Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Pitavastatin Sodium

FDA-approved product (tablet, oral), marketed as Livalo, Pitavastatin Calcium, Zypitamag and 1 more.

Registered studies
18
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Pitavastatin Sodium
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Abnormal circulating lipid concentration
  • Cardiovascular disease
  • Familial hypercholesterolemia
  • Hypercholesterolemia
  • Hyperlipidemia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Hmg coa reductase inhibitors
FDA pharmacologic class
HMG-CoA Reductase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA50.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli27.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae19.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis66.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

18registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Pitavastatin Sodium in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Pitavastatin Sodium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Livalozet Versus High-intensity Statin in Older Patients With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention

    NCT07626840 · start 2026-06-01

    Registered record
    Registry ID
    NCT07626840
    Conditions
    Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)
    Interventions
    Pitavastatin/ezetimibe; Atorvastatin or Rosuvastatin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2026-06-01
    Completion
    2031-12-31
    Enrolment
    5,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)
    InterventionPitavastatin/ezetimibe; Atorvastatin or Rosuvastatin
    PhaseNot applicable
    Registry statusNot yet recruiting

  • TRIal of STatin Therapy Effect on Androgen Status and Erectile functioN in Men

    NCT07460960 · start 2026-03-05

    Registered record
    Registry ID
    NCT07460960
    Conditions
    Erectile Dysfunction Due to Arterial Disease; Atheroscleroses; Erectile Disfunction; Endothelial Dysfunction; Androgen Profile; Testosterone
    Interventions
    Pitavastatin 1-4 mg daily; Rosuvastatin 20-40 mg daily
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2026-03-05
    Completion
    2027-12
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionErectile Dysfunction Due to Arterial Disease; Atheroscleroses; Erectile Disfunction; Endothelial Dysfunction +2 more
    InterventionPitavastatin 1-4 mg daily; Rosuvastatin 20-40 mg daily
    PhasePhase 2
    Registry statusRecruiting

  • Early Statin-Ezetimibe Combination vs. Statin Monotherapy in Stroke With Atherosclerosis

    NCT07307989 · start 2025-08-01

    Registered record
    Registry ID
    NCT07307989
    Conditions
    Ischemic Stroke; Hypercholesteremia
    Interventions
    statin + ezetimibe; Statin monotherapy (rosuvastatin or atorvastatin)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-08-01
    Completion
    2029-07-31
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIschemic Stroke; Hypercholesteremia
    Interventionstatin + ezetimibe; Statin monotherapy (rosuvastatin or atorvastatin)
    PhasePhase 2
    Registry statusRecruiting

  • A Study Investigating the Safety of RO7795081 and the Effect of RO7795081 on How the Body Processes Pitavastatin and Rosuvastatin in Otherwise Healthy Overweight or Obese Adult Participants

    NCT06982131 · start 2025-06-04

    Registered record
    Registry ID
    NCT06982131
    Conditions
    Overweight; Obesity
    Interventions
    RO7795081; Placebo; Rosuvastatin; Pitavastatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Active not recruiting
    Start
    2025-06-04
    Completion
    2026-12-07
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOverweight; Obesity
    InterventionRO7795081; Placebo; Rosuvastatin; Pitavastatin
    PhasePhase 1
    Registry statusActive not recruiting

  • A Research Study of the Effect of Etavopivat on Other Drugs in Healthy Participants

    NCT06813924 · start 2025-02-06

    Registered record
    Registry ID
    NCT06813924
    Conditions
    Healthy Volunteers Sickle Cell Disease, Thalassemia
    Interventions
    Etavopivat; Digoxin; Pitavastatin; Metformin; Midazolam; Rosuvastatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2025-02-06
    Completion
    2025-05-27
    Enrolment
    37

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers Sickle Cell Disease, Thalassemia
    InterventionEtavopivat; Digoxin; Pitavastatin; Metformin +2 more
    PhasePhase 1
    Registry statusCompleted

  • Optimising Metabolic Management for People With Human Immunodeficiency Virus (HIV) on Integrase Based Antiretroviral Therapy (ART)

    NCT06317051 · start 2024-12-16

    Registered record
    Registry ID
    NCT06317051
    Conditions
    HIV Infections; Weight Gain
    Interventions
    Dapagliflozin 10mg Tab; Pitavastatin 4 Mg Oral Tablet; Rosuvastatin and Ezetimibe; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2024-12-16
    Completion
    2027-12
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections; Weight Gain
    InterventionDapagliflozin 10mg Tab; Pitavastatin 4 Mg Oral Tablet; Rosuvastatin and Ezetimibe; Placebo
    PhasePhase 3
    Registry statusActive not recruiting

  • Repurposed Drugs in Research for Cancer Clinical Trials- Pitavastatin

    NCT05977738 · start 2024-01-18

    Registered record
    Registry ID
    NCT05977738
    Conditions
    Glioblastoma Multiforme, Adult; Recurrent Glioblastoma
    Interventions
    Pitavastatin calcium
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Completed
    Start
    2024-01-18
    Completion
    2024-07-19
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlioblastoma Multiforme, Adult; Recurrent Glioblastoma
    InterventionPitavastatin calcium
    PhaseEarly phase 1
    Registry statusCompleted

  • Head Acupuncture Treat Residual Symptoms After Canalith Repositioning Procedure for BPPV

    NCT06001047 · start 2023-11-01

    Registered record
    Registry ID
    NCT06001047
    Conditions
    Benign Paroxysmal Positional Vertigo
    Interventions
    Group A; Group B
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2023-11-01
    Completion
    2026-11-01
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBenign Paroxysmal Positional Vertigo
    InterventionGroup A; Group B
    PhaseNot applicable
    Registry statusRecruiting

  • Evaluation of the Pharmacokinetics of Microdose Midazolam, Dabigatran, Pitavastatin, Atorvastatin and Rosuvastatin in Diabetic Patients

    NCT06273215 · start 2023-03-05

    Registered record
    Registry ID
    NCT06273215
    Conditions
    Diabetes
    Interventions
    The combinations of 10 µg midazolam, 375 µg dabigatran etexilate, 10 µg pitavastatin, 50 µg rosuvastatin, and 100 µg atorvastatin were administered to diabetic patients on an empty stomach.
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2023-03-05
    Completion
    2025-12-31
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes
    InterventionThe combinations of 10 µg midazolam, 375 µg dabigatran etexilate, 10 µg pitavastatin, 50 µg rosuvastatin, and 100 µg atorvastatin were administered to diabetic patients on an empty stomach.
    PhasePhase 4
    Registry statusUnknown

  • A Clinical Study to Evaluate the Pharmacokinetics of Microdose Midazolam, Dabigatran, Pitavastatin, Atorvastatin and Rosuvastatin in Healthy Volunteers and Renal Impairment Patients

    NCT05747768 · start 2022-07-15

    Registered record
    Registry ID
    NCT05747768
    Conditions
    Chronic Kidney Disease
    Interventions
    Midazolam, dabigatran etexilate, pitavastatin, rosuvastatin and atorvastatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2022-07-15
    Completion
    2024-12-31
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Kidney Disease
    InterventionMidazolam, dabigatran etexilate, pitavastatin, rosuvastatin and atorvastatin
    PhasePhase 4
    Registry statusUnknown

  • Real World Evidence Study of Statin Use in Brazil

    NCT05285085 · start 2021-11-19

    Registered record
    Registry ID
    NCT05285085
    Conditions
    Cardiovascular Diseases; Myocardial Infarction; Stroke; Hypertension; Diabetes Mellitus; Dyslipidemias
    Interventions
    Statin
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2021-11-19
    Completion
    2021-12-15
    Enrolment
    2,133,900

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiovascular Diseases; Myocardial Infarction; Stroke; Hypertension +2 more
    InterventionStatin
    PhaseNot recorded
    Registry statusCompleted

  • China Protection Trial of Glucose Metabolism by Pitavastatin in Patients With Prediabetes and Hypertension

    NCT03532620 · start 2018-08-09

    Registered record
    Registry ID
    NCT03532620
    Conditions
    Prediabetic State; Hypertension; Dyslipidemias
    Interventions
    Pitavastatin Calcium; Atorvastatin Calcium
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2018-08-09
    Completion
    2020-09
    Enrolment
    396

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrediabetic State; Hypertension; Dyslipidemias
    InterventionPitavastatin Calcium; Atorvastatin Calcium
    PhasePhase 4
    Registry statusUnknown

  • Pharmacokinetics of Midazolam, Dabigatran, Pitavastatin, Atorvastatin, and Rosuvastatin in Participants With Renal Insufficiency in the Presence and Absence of Rifampin (MK-0000-386)

    NCT03311841 · start 2018-03-01

    Registered record
    Registry ID
    NCT03311841
    Conditions
    Renal Insufficiency
    Interventions
    Midazolam oral solution; Dabigatran and pitavastatin oral solution; Atorvastatin and rosuvastatin oral solution; Rifampin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-03-01
    Completion
    2018-08-02
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRenal Insufficiency
    InterventionMidazolam oral solution; Dabigatran and pitavastatin oral solution; Atorvastatin and rosuvastatin oral solution; Rifampin
    PhasePhase 1
    Registry statusCompleted

  • Safety and Efficacy of Statins for Chinese Patients With Dyslipidemia

    NCT03418974 · start 2017-11-01

    Registered record
    Registry ID
    NCT03418974
    Conditions
    Dyslipidemias
    Interventions
    Pitavastatin; Atorvastatin; Rosuvastatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2017-11-01
    Completion
    2021-12-31
    Enrolment
    10,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDyslipidemias
    InterventionPitavastatin; Atorvastatin; Rosuvastatin
    PhasePhase 4
    Registry statusUnknown

  • to Evaluate the Safety and Efficacy of Pitavastatin in Patients With IFG and Hyperlipidemia

    NCT02056847 · start 2013-09

    Registered record
    Registry ID
    NCT02056847
    Conditions
    HbA1c Level Associated With Lipid Compositions
    Interventions
    Pitavastatin calcium 4mg; Pitavastatin calcium 2mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2013-09
    Completion
    2017-05
    Enrolment
    313

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHbA1c Level Associated With Lipid Compositions
    InterventionPitavastatin calcium 4mg; Pitavastatin calcium 2mg
    PhasePhase 4
    Registry statusCompleted